# Staying Well After Depression: a randomised trial

Submission date [ ] Prospectively registered Recruitment status 04/01/2010 No longer recruiting [X] Protocol [ ] Statistical analysis plan Registration date Overall study status 05/01/2010 Completed [X] Results [ ] Individual participant data **Last Edited** Condition category 24/02/2015 Mental and Behavioural Disorders

#### Plain English summary of protocol

http://www.staying-well.org/information-sheet

# **Contact information**

#### Type(s)

Scientific

#### Contact name

Prof Mark Williams

#### Contact details

Department of Psychiatry University of Oxford Warneford Hospital Warneford Lane Headington Oxford United Kingdom OX3 7JX

## Additional identifiers

#### Protocol serial number

Protocol version 5 (6/5/09); 067797

# Study information

#### Scientific Title

Modifying risk and severity of relapse in patients with recurrent depression at high suicide risk: translational randomised controlled trial

#### Acronym

**SWAD** 

#### **Study objectives**

That treatment with mindfulness-based cognitive therapy for depression, a novel form of treatment combining mindfulness meditation and cognitive therapy for depression, delivered in addition to treatment as usual (TAU), will:

- 1. Reduce risk of relapse to major depression in recurrently depressed patients compared with TAU alone and cognitive psycho-education (CPE), a treatment of equal plausibility, and
- 2. Reduce incidence of suicidal symptoms in those with a history of suicidality compared with TAU alone

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Oxfordshire Research Ethics Committee (REC) C, 27/06/2008, ref: 08/H606/56

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Prevention

#### Health condition(s) or problem(s) studied

Recurrent depression

#### **Interventions**

Mindfulness-based cognitive therapy and cognitive psychoeducation as compared to ordinary care (treatment-as-usual).

Treatment duration: 8 weeks Follow-up duration: 12 months

#### Intervention Type

Behavioural

#### Primary outcome(s)

Time to relapse or recurrence meeting DSM-IV criteria for major depression, assessed using the Structured Clinical Interview for DSM-IV (SCID). Occurrence of relapse/recurrence is assessed at all follow-up assessments, and 'return to treatment' will be treated as a relapse/recurrence if, in the judgment of a blind assessor, the participant has experienced exacerbation of symptoms that would have met the criteria for major depression in the absence of immediate treatment. In addition to diagnostic status, we assess severity of depression and hopelessness using a number of interview and self-report measures including the Hamilton Rating Scale for Depression, the Beck Depression Inventory and the Beck Hopelessness Scale, at all time points. These quantitative measures complement the dichotomised outcome of diagnosis.

Outcomes measured pre-treatment, post-treatment and at 3, 6, 9, and 12 months follow-up.

#### Key secondary outcome(s))

1. Cognitive measures relevant to risk of relapse/recurrence (mindfulness, self-compassion, rumination, self discrepancy, autobiographical memory, and executive capacity) are assessed before and immediately after the treatment as well as at the end of the follow-up, and will be used in an explanatory analysis to examine factors that mediate and moderate efficacy 2. Severity of suicidal ideation/behaviour both within and between episodes of depression during the follow-up period

Outcomes measured pre-treatment, post-treatment and at 3, 6, 9, and 12 months follow-up.

#### Completion date

31/12/2011

# Eligibility

#### Key inclusion criteria

- 1. Aged 18 years or over, and not older than 70 years due to the fact that depression in old age has often been found to be related to different factors than depression in earlier stages of life. Male or female.
- 2. Meeting enhanced Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for a history of recurrent major depression, i.e. history of at least three episodes of depression, two of which must have occurred within the last five years, of which one must have occurred within the last two years. Although previous suicidality is recorded in detail (which allows stratification to be carried out on this basis) participants are not included/excluded from the study on the basis of their prior experience of suicidality.
- 3. Meeting the National Institute of Mental Health (NIMH) guidelines for recovery or remission at the time of baseline assessment. For the purposes of the trial participants are NOT deemed to be in recovery or remission (and hence are ineligible) if they report a week (or more) during the previous 8 weeks during which they experienced EITHER a core symptom of depression (depressed mood, anhedonia) or suicidal feelings AND at least one other symptom of depression, which together are not accounted for by bereavement or substances/general medical conditions, and which are accompanied by significant impairment in functioning.
- 4. Giving informed consent
- 5. Consent received from the participant's General Practitioner

#### Participant type(s)

Patient

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Lower age limit

18 years

Sex

#### Key exclusion criteria

Participants are excluded from the study if one or more of the following apply:

- 1. They have a history of schizophrenia, schizoaffective disorder, bipolar I disorder, current and severe substance abuse, organic mental disorder, pervasive developmental delay, a primary diagnosis of obsessive-compulsive disorder or eating disorder, or are currently regularly self-harming
- 2. They are showing a positive and continuing response to CBT
- 3. They have current psychotherapy or counseling more frequently than once per month
- 4. They are unable to complete the baseline research assessment (e.g. due to difficulties with English, visual impairment, or cognitive difficulties)

# Date of first enrolment

01/10/2008

#### Date of final enrolment

31/12/2011

# Locations

#### Countries of recruitment

**United Kingdom** 

England

# Study participating centre University of Oxford

Oxford United Kingdom OX3 7JX

# Sponsor information

#### Organisation

University of Oxford (UK)

#### ROR

https://ror.org/052gg0110

# Funder(s)

Funder type

#### Charity

#### **Funder Name**

Wellcome Trust

#### Alternative Name(s)

### **Funding Body Type**

Private sector organisation

#### Funding Body Subtype

International organizations

#### Location

United Kingdom

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type	Details	Date created Date added	d Peer reviewed?	Patient-facing?
Results article	results	01/02/2014	Yes	No
Results article	results	02/07/2014	Yes	No
Protocol article	protocol	19/03/2010	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	5 No	Yes
Study website	Study website	11/11/2025 11/11/202	5 No	Yes